Goldman Sachs Group »

Aeglea Biotherapeutics shares owned by Goldman Sachs Group

Quarter-by-quarter ownership of Aeglea Biotherapeutics (SYRE) shares owned by Goldman Sachs Group from 13F filings

Historical chart of Goldman Sachs Group investment in Aeglea Biotherapeutics

Tip: Access up to 7 years of quarterly data

All positions including Aeglea Biotherapeutics held by Goldman Sachs Group consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Aeglea Biotherapeutics by Goldman Sachs Group

Quarter filed Position value Share count Share price at filing
2024-06-30 $21M 893k 23.51
2024-03-31 $9.1M 240k 37.93

More positions owned by Goldman Sachs Group

Spdr S&p 500 Etf Tr CMN (SPY)
Nvidia Corporation CMN (NVDA)
Microsoft Corp CMN (MSFT)
Apple CMN (AAPL)
Amazon CMN (AMZN)
Alphabet CMN (GOOGL)
Tesla CMN (TSLA)
Meta Platforms CMN (META)
Ishares Tr CMN (IVV)
Invesco Qqq Tr CMN (QQQ)
Ishares Tr CMN (IWM)
Vanguard Index Fds CMN (VOO)
Alphabet CMN (GOOG)
Visa CMN (V)
Ishares Tr CMN (EEM)

View all positions for Goldman Sachs Group

Top funds holding Aeglea Biotherapeutics

Fairmount Funds Management
Perceptive Advisors
VR Adviser
BlackRock
BlackRock
Braidwell
Commodore Capital
Vanguard Group
Deep Track Capital
State Street Corporation
Paradigm Biocapital Advisors
Assenagon Asset Management
Goldman Sachs Group
Geode Capital Management
Pictet Asset Management Holding SA

View all funds holding Aeglea Biotherapeutics